PH12019501212A1 - Pyrazole derivatives as malt1 inhibitors - Google Patents
Pyrazole derivatives as malt1 inhibitorsInfo
- Publication number
- PH12019501212A1 PH12019501212A1 PH12019501212A PH12019501212A PH12019501212A1 PH 12019501212 A1 PH12019501212 A1 PH 12019501212A1 PH 12019501212 A PH12019501212 A PH 12019501212A PH 12019501212 A PH12019501212 A PH 12019501212A PH 12019501212 A1 PH12019501212 A1 PH 12019501212A1
- Authority
- PH
- Philippines
- Prior art keywords
- pyrazole derivatives
- malt1 inhibitors
- malt1
- inhibitors
- compounds
- Prior art date
Links
- 229940122339 MALT1 inhibitor Drugs 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101150113681 MALT1 gene Proteins 0.000 abstract 1
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 abstract 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437384P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/067516 WO2018119036A1 (en) | 2016-12-21 | 2017-12-20 | Pyrazole derivatives as malt1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019501212A1 true PH12019501212A1 (en) | 2019-12-16 |
Family
ID=61628454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019501212A PH12019501212A1 (en) | 2016-12-21 | 2019-05-31 | Pyrazole derivatives as malt1 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10954214B2 (enExample) |
| EP (1) | EP3558969B1 (enExample) |
| JP (1) | JP7138641B2 (enExample) |
| KR (1) | KR102583317B1 (enExample) |
| CN (1) | CN110214136A (enExample) |
| AR (1) | AR110421A1 (enExample) |
| AU (2) | AU2017382185C1 (enExample) |
| BR (1) | BR112019012355A2 (enExample) |
| CA (1) | CA3048027A1 (enExample) |
| CL (1) | CL2019001709A1 (enExample) |
| CO (1) | CO2019006622A2 (enExample) |
| EA (1) | EA201991503A1 (enExample) |
| ES (1) | ES2992411T3 (enExample) |
| IL (1) | IL267343B2 (enExample) |
| MA (1) | MA47125A (enExample) |
| MX (2) | MX392673B (enExample) |
| PE (1) | PE20191755A1 (enExample) |
| PH (1) | PH12019501212A1 (enExample) |
| TN (1) | TN2019000192A1 (enExample) |
| TW (1) | TWI795381B (enExample) |
| UA (1) | UA127920C2 (enExample) |
| UY (1) | UY37537A (enExample) |
| WO (1) | WO2018119036A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| IL273428B2 (en) | 2017-09-22 | 2023-09-01 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| BR112020008851A2 (pt) | 2017-11-06 | 2020-10-20 | Jubilant Prodel LLC | composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas |
| JP7368369B2 (ja) | 2017-11-24 | 2023-10-24 | ジュビラント・エピスクライブ・エルエルシー | Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物 |
| CN111770759A (zh) | 2017-12-28 | 2020-10-13 | 通用医疗公司 | 靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎 |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| BR112020022936A2 (pt) | 2018-05-11 | 2021-02-02 | Incyte Corporation | derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1 |
| KR20210024002A (ko) * | 2018-06-18 | 2021-03-04 | 얀센 파마슈티카 엔.브이. | Malt1 억제제로서의 피라졸 유도체 |
| MX2020013899A (es) * | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| TW202045008A (zh) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| WO2020169738A1 (en) * | 2019-02-22 | 2020-08-27 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| ES2966132T3 (es) * | 2019-02-22 | 2024-04-18 | Janssen Pharmaceutica Nv | Forma cristalina de monohidrato de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-(2-(trifluorometil)piridin-4-il)- 1h-pirazol-4-carboxamida |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| MX2022003578A (es) | 2019-09-30 | 2022-05-30 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores. |
| EP4048659A4 (en) * | 2019-10-24 | 2023-11-29 | ONO Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
| JP7758665B2 (ja) * | 2019-10-30 | 2025-10-22 | バイオジェン・エムエイ・インコーポレイテッド | Ｂｔｋ阻害剤としての縮合ピリダジンまたはピリミジン |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| EP4061966A1 (en) * | 2019-11-22 | 2022-09-28 | Janssen Pharmaceutica NV | Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors |
| AU2020385647A1 (en) * | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| WO2021138298A1 (en) * | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
| WO2022038252A1 (en) | 2020-08-21 | 2022-02-24 | Janssen Pharmaceutica Nv | Amorphous form of a malt1 inhibitor and formulations thereof |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| CN116916924A (zh) * | 2020-10-16 | 2023-10-20 | 稀有生物科学股份有限公司 | Malt1调节剂及其用途 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| CN116710089A (zh) * | 2020-11-12 | 2023-09-05 | 莫诺泰罗斯疗法公司 | 治疗癌症的材料和方法 |
| GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| US20240132475A1 (en) * | 2021-02-04 | 2024-04-25 | Aurigene Oncology Limited | Substituted pyrazolyl compounds as malt-1 inhibitors |
| CN117279639A (zh) | 2021-03-03 | 2023-12-22 | 詹森药业有限公司 | 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| WO2022262855A1 (zh) * | 2021-06-18 | 2022-12-22 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
| WO2023279986A1 (zh) * | 2021-07-05 | 2023-01-12 | 贝达药业股份有限公司 | 六元芳基或杂芳基酰胺类化合物及其组合物和用途 |
| CN117794540A (zh) | 2021-08-09 | 2024-03-29 | 詹森药业有限公司 | 用于治疗b细胞恶性肿瘤的组合物 |
| CN113912511B (zh) * | 2021-11-29 | 2024-02-13 | 广东广康生化科技股份有限公司 | 一种联苯肼酯中间体的合成方法 |
| JP2025501056A (ja) | 2021-12-30 | 2025-01-17 | シャンハイ ハンソー バイオメディカル カンパニー リミテッド | 三環系誘導体阻害剤、その製造方法と応用 |
| KR20240144146A (ko) | 2022-02-02 | 2024-10-02 | 오노 야꾸힝 고교 가부시키가이샤 | Malt1 저해약을 유효 성분으로서 포함하는 암 치료제 |
| EP4472734A1 (en) * | 2022-02-03 | 2024-12-11 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
| TW202430031A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| EP4626882A1 (en) | 2022-11-30 | 2025-10-08 | Syngenta Crop Protection AG | Microbiocidal tetrahydroisoquinoline derivatives |
| WO2024125628A1 (zh) * | 2022-12-16 | 2024-06-20 | 江苏恒瑞医药股份有限公司 | 一种Malt 1抑制剂的磷酸酯前药 |
| WO2025002340A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海翰森生物医药科技有限公司 | 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用 |
| WO2025002333A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海翰森生物医药科技有限公司 | 一种三并环类衍生物抑制剂的晶型及其制备方法 |
| WO2025069270A1 (ja) * | 2023-09-27 | 2025-04-03 | 日本新薬株式会社 | アザインドール化合物及び医薬 |
| WO2025073968A1 (en) | 2023-10-06 | 2025-04-10 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
| WO2025210096A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Fungicidal compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| AU2004235755A1 (en) * | 2003-04-30 | 2004-11-18 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer |
| WO2004098518A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
| JPWO2006085685A1 (ja) | 2005-02-09 | 2008-06-26 | 武田薬品工業株式会社 | ピラゾール化合物 |
| CN100526430C (zh) | 2005-10-19 | 2009-08-12 | 中国石油化工股份有限公司 | 一种生产清洁汽油的方法 |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| JP2009533327A (ja) | 2006-03-22 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤 |
| CA2657660A1 (en) | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| KR20100015414A (ko) | 2007-03-09 | 2010-02-12 | 하이 포인트 파마슈티칼스, 엘엘씨 | 히드록시스테로이드 탈수소효소 억제제로서 인돌- 및 벤즈이미다졸 아미드 |
| CN101366715A (zh) | 2007-08-15 | 2009-02-18 | 上海医药工业研究院 | 一种雷帕霉素组合物及其制备方法 |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| KR101364869B1 (ko) | 2008-09-24 | 2014-02-21 | 바스프 에스이 | 무척추 해충을 방제하기 위한 피라졸 화합물 |
| WO2010039039A1 (en) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| JP5984801B2 (ja) | 2010-06-22 | 2016-09-06 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | ４−ヒドロキシピリジン類の製造方法 |
| WO2012004217A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| WO2012063896A1 (ja) | 2010-11-11 | 2012-05-18 | 第一三共株式会社 | 新規ピラゾールアミド誘導体 |
| WO2013178591A1 (en) | 2012-05-31 | 2013-12-05 | F. Hoffmann-La Roche Ag | Aminoquinazoline and pyridopyrimidine derivatives |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| US9592223B2 (en) | 2012-11-09 | 2017-03-14 | Cornell University | Small molecule inhibitors of MALT1 |
| WO2014086478A1 (en) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of malt1 protease |
| EA201500736A1 (ru) | 2013-01-10 | 2016-04-29 | Грюненталь Гмбх | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов |
| JP2015096499A (ja) * | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
| PL3149001T3 (pl) | 2014-05-28 | 2019-10-31 | Novartis Ag | Nowe pochodne pirazolopirymidyny i ich zastosowanie jako inhibitory MALT1 |
| US20150361504A1 (en) | 2014-06-13 | 2015-12-17 | Pharmacyclics Llc | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016005994A2 (en) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| US9730938B2 (en) | 2014-08-08 | 2017-08-15 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| ES2819871T3 (es) | 2014-09-10 | 2021-04-19 | Glaxosmithkline Ip Dev Ltd | Compuestos utilizados como inhibidores de la quinasa reordenada durante la transfección (RET) |
| AU2015357498B2 (en) | 2014-12-06 | 2019-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016209688A1 (en) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of cancer and uses thereof |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| US20200289514A1 (en) * | 2015-11-13 | 2020-09-17 | Novartis Ag | Novel Pyrazolo Pyrimidine Derivatives |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| WO2017151786A1 (en) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| JP2019522035A (ja) | 2016-07-29 | 2019-08-08 | ルピン・リミテッド | Ｍａｌｔ１阻害剤としての置換チアゾロ−ピリジン化合物 |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| ES2856248T3 (es) | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| WO2018115880A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| WO2018165385A1 (en) | 2017-03-08 | 2018-09-13 | Cornell University | Inhibitors of malt1 and uses thereof |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| CN111770759A (zh) | 2017-12-28 | 2020-10-13 | 通用医疗公司 | 靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎 |
| CN111801245B (zh) | 2018-02-23 | 2024-04-30 | 工业设备运营公司 | 产生磁场的设备以及对交通工具动态充电的感应式充电系统的初级装置 |
| KR20210024002A (ko) | 2018-06-18 | 2021-03-04 | 얀센 파마슈티카 엔.브이. | Malt1 억제제로서의 피라졸 유도체 |
| MX2020013899A (es) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| WO2020169738A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| ES2966132T3 (es) | 2019-02-22 | 2024-04-18 | Janssen Pharmaceutica Nv | Forma cristalina de monohidrato de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-(2-(trifluorometil)piridin-4-il)- 1h-pirazol-4-carboxamida |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| EP4061966A1 (en) | 2019-11-22 | 2022-09-28 | Janssen Pharmaceutica NV | Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors |
| AU2020385647A1 (en) | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| WO2022038252A1 (en) | 2020-08-21 | 2022-02-24 | Janssen Pharmaceutica Nv | Amorphous form of a malt1 inhibitor and formulations thereof |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| CN117279639A (zh) | 2021-03-03 | 2023-12-22 | 詹森药业有限公司 | 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 |
-
2017
- 2017-12-19 TW TW106144535A patent/TWI795381B/zh active
- 2017-12-20 MX MX2019007540A patent/MX392673B/es unknown
- 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
- 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
- 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en not_active Ceased
- 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active Active
- 2017-12-20 EP EP17851862.7A patent/EP3558969B1/en active Active
- 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
- 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
- 2017-12-20 ES ES17851862T patent/ES2992411T3/es active Active
- 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
- 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
- 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
- 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt not_active Application Discontinuation
- 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
- 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
- 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en active Active
- 2017-12-21 UY UY0001037537A patent/UY37537A/es not_active Application Discontinuation
- 2017-12-21 AR ARP170103626A patent/AR110421A1/es not_active Application Discontinuation
-
2019
- 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
- 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
- 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
- 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
- 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
-
2020
- 2020-11-25 US US17/104,081 patent/US12077521B2/en active Active
-
2022
- 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005827A (es) | Derivados de pirazol como inhibidores de malt1. | |
| PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| PH12020552207A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| ZA202101788B (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2021012417A (es) | Anillos de piridina que contienen derivados como inhibidores de malt1. | |
| MX367852B (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
| MX394038B (es) | Derivados de pirrolotriazina como inhibidores de cinasas. | |
| MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |